CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.50
+0.03 (0.30%)
At close: Apr 11, 2025, 4:00 PM
8.52
+0.03 (0.33%)
After-hours: Apr 11, 2025, 7:57 PM EDT
CervoMed Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for CervoMed stock have an average target of 25.43, with a low estimate of 10 and a high estimate of 63. The average target predicts an increase of 199.35% from the current stock price of 8.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CervoMed stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 4 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 4 | 4 | 3 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +17.72% | Mar 26, 2025 |
| Roth MKM | Roth MKM | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +135.43% | Mar 18, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $21 | Strong Buy | Maintains | $12 → $21 | +147.20% | Mar 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +64.80% | Mar 18, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +17.72% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
6.09M
from 9.74M
Decreased by -37.47%
Revenue Next Year
n/a
from 6.09M
EPS This Year
-2.01
from -2.02
EPS Next Year
-1.94
from -2.01
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.5M | n/a | n/a | ||
| Avg | 6.1M | n/a | n/a | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.1% | - | - | ||
| Avg | -37.5% | - | - | ||
| Low | -76.9% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.35 | -0.66 | -0.36 | ||
| Avg | -2.01 | -1.94 | -1.51 | ||
| Low | -2.63 | -2.94 | -2.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.